US Patent

US9271931 — Compositions for delivery of drug combinations

Formulation · Assigned to Celator Pharmaceuticals Inc · Expires 2027-01-23 · 1y remaining

Vulnerability score 43/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects compositions that deliver non-antagonistic combinations of two or more agents, such as antineoplastic agents, in a stable form.

USPTO Abstract

Compositions which comprise delivery vehicles having stably associated therewith non-antagonistic combinations of two or more agents, such as antineoplastic agents, are useful in achieving non-antagonistic effects when combinations of drugs are administered.

Drugs covered by this patent

Cytarabine (Cytarabine) · Nippon Shinyaku Co., Ltd.

Patent Metadata

Patent number: US9271931
Jurisdiction: US
Classification: Formulation
Expires: 2027-01-23
Drug substance claim: No
Drug product claim: Yes
Assignee: Celator Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.